{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:27:19Z","timestamp":1793906839107,"version":"4.8.0"},"reference-count":37,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background. Monoclonal antibodies (mAbs) directed against the calcitonin gene-related peptide (CGRP) or its receptor represented the first targeted and specialized approach to migraine prophylaxis. Nevertheless, they have been rarely considered in the treatment of vestibular migraine (VM). Our aim was to evaluate the effectiveness of anti-CGRP mAbs in VM patients who did not respond to conventional migraine treatments. Methods. Consecutive VM patients treated with erenumab were considered. As a comparison, we considered the same VM patients during conventional migraine treatments (i.e., propranolol, flunarizine, or valproic acid), which were tried before mAbs therapy. Videonystagmography, the Italian version of the Dizziness Handicap Inventory (DHI) questionnaire, and migraine days over the last 3 months were evaluated in all patients before and after treatments. Results. In the present retrospective study, we included 21 female and 2 male VM patients, mean age 45.2 years. All patients underwent contrast-enhanced magnetic resonance imaging that ruled out other causes of vertigo. The DHI questionnaire significantly improved after mAb therapy (p &lt; 0.0001). Mean migraine days over the last 3 months were significantly reduced after treatment (p = 0.001). Videonystagmography was altered in 11 (48%) patients prior to monoclonal antibodies. We found vertical positional nystagmus in 9 patients and horizontal positional nystagmus in 2 patients. After the treatment, we found vertical positional nystagmus only in 1 patient (p = 0.002). When patients were treated with conventional therapies, there was no significant reduction in DHI, and instrumental vestibular examinations remained altered. Conclusions. VM patients using anti-CGRP mAbs experienced a reduction in the dizziness-derived handicap, as reported in the DHI questionnaire. Furthermore, these treatments were significantly associated with a normalization of vestibular instrumental analysis. These findings were not seen with conventional treatments. Treatment with anti-CGRP mAbs may be effective in VM patients who did not respond to conventional migraine treatments. These findings should be tested in large, randomized clinical trials.<\/jats:p>","DOI":"10.3390\/medicina59091560","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:46:47Z","timestamp":1693201607000},"page":"1560","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine"],"prefix":"10.3390","volume":"59","author":[{"given":"Andrea","family":"Lovato","sequence":"first","affiliation":[{"name":"Otorhinolaryngology Unit, Department of Surgical Specialties, Vicenza Civil Hospital, 36100 Vicenza, Italy"},{"name":"Otorhinolaryngology Unit, Department of Surgical Specialties, San Gaetano Clinic, 36016 Thiene, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Disco","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Neuroscience, Vicenza Civil Hospital, 36100 Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1347-4013","authenticated-orcid":false,"given":"Andrea","family":"Frosolini","sequence":"additional","affiliation":[{"name":"Maxillofacial Surgery Unit, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Monzani","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology Unit, Department of Surgical Specialties, University of Verona, 37100 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Perini","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Neuroscience, Vicenza Civil Hospital, 36100 Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s004150050478","article-title":"Episodic vertigo related to migraine (90 cases): Vestibular migraine?","volume":"246","author":"Dieterich","year":"1999","journal-title":"Neurol. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/VES-2012-0453","article-title":"Vestibular migraine: Diagnostic criteria","volume":"22","author":"Lempert","year":"2012","journal-title":"Vestib. J. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/MAO.0000000000001900","article-title":"The epidemiology of vestibular migraine: A population-based survey study","volume":"39","author":"Formeister","year":"2018","journal-title":"Otol. Neurotol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00415-022-11532-x","article-title":"Vestibular migraine or Meniere\u2019s disease: A diagnostic dilemma","volume":"270","author":"Chen","year":"2023","journal-title":"J. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1212\/01.WNL.0000049476.40047.A3","article-title":"Zolmitriptan for treatment of migrainous vertigo: A placebo-controlled trial","volume":"60","author":"Neuhauser","year":"2003","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11910-022-01222-6","article-title":"Vestibular Migraine","volume":"22","author":"Beh","year":"2022","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin gene-related peptide: Physiology and pathophysiology","volume":"94","author":"Russell","year":"2014","journal-title":"Physiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1007\/s00415-015-7905-2","article-title":"Vestibular migraine: The most frequent entity of episodic vertigo","volume":"263","author":"Dieterich","year":"2016","journal-title":"Neurol. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1474-4422(13)70107-8","article-title":"Vestibular migraine: Clinical aspects and pathophysiology","volume":"12","author":"Furman","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_10","first-page":"369","article-title":"Episodic spontaneous dizziness","volume":"27","author":"Eggers","year":"2021","journal-title":"Continuum."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1055\/s-0039-3402735","article-title":"Vestibular migraine i: Mechanisms, diagnosis, and clinical features","volume":"40","author":"Baloh","year":"2020","journal-title":"Semin. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Xiaocheng, W., Zhaohui, S., Junhui, X., Lei, Z., Lining, F., and Zuoming, Z. (2012). Expression of calcitonin gene-related peptide in efferent vestibular system and vestibular nucleus in rats with motion sickness. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047308"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s10194-020-01145-y","article-title":"Calcitonin gene-related peptide facilitates sensitization of the vestibular nucleus in a rat model of chronic migraine","volume":"21","author":"Zhang","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s10194-022-01403-1","article-title":"Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC\/ERK\/CREB pathway in an experimental chronic migraine rat model","volume":"23","author":"Tian","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/cne.902960402","article-title":"Expression of c-fos-like protein as a marker for neuronal activity following noxious stimulation in the rat","volume":"296","author":"Bullitt","year":"1990","journal-title":"J. Comp. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rahman, S.M., Hauser, C., Faucher, S., Fine, E., and Luebke, A.E. (2023). Both systemic Calcitonin Gene Related Peptide (CGRP) and a vestibular challenge promote anxiety-related behaviors and dynamic imbalance in mice. bioRxiv, preprint.","DOI":"10.1101\/2023.06.30.547257"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","article-title":"Calcitonin gene-related peptide (CGRP): A new target for migraine","volume":"55","author":"Russo","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/1060028019835166","article-title":"Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention","volume":"53","author":"Garland","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"649143","DOI":"10.3389\/fphar.2021.649143","article-title":"Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: A systematic review and network meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/0333102421989601","article-title":"AntiCGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis","volume":"41","author":"Drellia","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","article-title":"CGRP monoclonal antibodies in migraine: An efficacy and tolerability comparison with standard prophylactic drugs","volume":"22","author":"Vandervorst","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/WCO.0000000000000689","article-title":"How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient\u2019s perspective","volume":"32","author":"Alpuente","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"799002","DOI":"10.3389\/fneur.2021.799002","article-title":"New Anti-CGRP Medications in the Treatment of Vestibular Migraine","volume":"12","author":"Hoskin","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","article-title":"Predictors of response to anti-CGRP monoclonal antibodies: A 24-week, multicenter, prospective study on 864 migraine patients","volume":"23","author":"Barbanti","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"NP60","DOI":"10.1177\/0145561320980183","article-title":"Physical Therapy for Benign Positional Vertigo of Posterior Canal: The Role of Alternated Epley and Semont Maneuvers","volume":"102","author":"Lovato","year":"2021","journal-title":"Ear Nose Throat J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/00016489.2021.1913288","article-title":"Higher incidence of M\u00e9ni\u00e8re\u2019s disease during COVID-19 pandemic: A preliminary report","volume":"141","author":"Lovato","year":"2021","journal-title":"Acta Otolaryngol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1515\/sjpain-2021-0102","article-title":"High score of dizziness-handicap-inventory (DHI) in patients with chronic musculoskeletal pain makes a chronic vestibular disorder probable","volume":"22","author":"Iglebekk","year":"2022","journal-title":"Scand J. Pain."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1007\/s00405-022-07366-y","article-title":"Depression scores and quality of life of vertiginous patients, suffering from different vestibular disorders","volume":"279","author":"Maihoub","year":"2022","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.1007\/s00415-022-11250-4","article-title":"Outcome of vestibular rehabilitation in vestibular migraine","volume":"269","author":"Balci","year":"2022","journal-title":"J. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"103152","DOI":"10.1016\/j.amjoto.2021.103152","article-title":"Vestibular and oculomotor function in patients with vestibular migraine","volume":"42","author":"Fu","year":"2021","journal-title":"Am. J. Otolaryngol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/lary.25445","article-title":"Propranolol and venlafaxine for vestibular migraine prophylaxis: A randomized controlled trial","volume":"126","author":"Salviz","year":"2016","journal-title":"Laryngoscope"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3331024231161809","DOI":"10.1177\/03331024231161809","article-title":"Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study","volume":"43","author":"Russo","year":"2023","journal-title":"Cephalalgia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1186\/s13063-019-3903-5","article-title":"Results and lessons learnt from a randomized controlled trial: Prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG)","volume":"20","author":"Bayer","year":"2019","journal-title":"Trials"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1007\/s00405-013-2786-4","article-title":"Flunarizine in the prophylaxis of migrainous vertigo","volume":"271","author":"Lepcha","year":"2014","journal-title":"Eur. Arch. Otolaryngol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Yiannakis, C., Hamilton, L., Slim, M., and Kontorinis, G. (2022). A systematic review and meta-analysis of prophylactic medication of vestibular migraine. J. Laryngol. Otol., 1\u20139.","DOI":"10.1017\/S0022215122001979"},{"key":"ref_36","first-page":"CD010600","article-title":"Pharmacological agents for the prevention of vestibular migraine","volume":"6","author":"Birdi","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/brain\/awac264","article-title":"Vestibular migraine treatment: A comprehensive practical review","volume":"145","author":"Smyth","year":"2022","journal-title":"Brain A J. Neurol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/9\/1560\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:40:50Z","timestamp":1760128850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/9\/1560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["medicina59091560"],"URL":"https:\/\/doi.org\/10.3390\/medicina59091560","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}